Screener
Tarsus Pharmaceuticals, Inc. TARS Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s long-term debt?
- Tarsus Pharmaceuticals, Inc. (TARS) reported long-term debt of $72.76M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s long-term debt increased by 0.9% year-over-year, from $72.13M to $72.76M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude